Why this matters: Citigroup downgraded BSX to Neutral this week, slashing its target to $50 from $57. That move crystallised a bear case that short sellers began pricing in weeks ago — short interest has nearly doubled over 30 days to 2.8% of float.
Citigroup's Joanne Wuensch pulled her Buy rating on September 17. The new $50 target sits 12% below the prior $57 and roughly 14% above the current price of $43.91. That gap looks wide — until you consider the consensus mean target is $62, implying the stock has further to fall before it reaches even the most cautious analyst's number.
The downgrade isn't isolated. BTIG's Marie Thibault cut her target to $56 from $60 on September 9, keeping a Buy but acknowledging deterioration. Argus Research dropped to Hold in July. The pattern is a slow-moving tide of reduced conviction, not a sudden collapse.
The bear case is concrete: radiofrequency ablation market share projected to drop from 34% to 23% by 2030. Cryoablation share slipping too. Pricing pressure in core businesses. Slower-than-expected product uptake.
Short interest stood at roughly 20.5 million shares on August 17. By September 16 it had reached 41.8 million — a 108% increase in one month. The one-week jump alone was 55.6%.
At 2.8% of float, the absolute level remains low. Borrowing shares is not difficult — availability is extremely loose at 8,546% relative to shares already borrowed. Cost to borrow sits at just 0.15%, down 50% over the past week. Short sellers face no meaningful squeeze pressure from the lending market.
The options market is leaning slightly bearish. The put/call ratio hit 0.43 on September 16, a z-score of 1.77 relative to the 20-day mean of 0.39. That's elevated but not extreme — more cautious positioning than outright panic.
The most striking counterpoint is insider buying. CEO Michael Mahoney made an open-market purchase of 186,240 shares on August 3 for approximately $9 million — no 10b5-1 plan attached. The CFO and two directors also bought in August. Net insider purchases over the past 90 days total roughly $9.5 million in value.
That's a significant cluster of discretionary buying at prices between $47 and $51 — well above where the stock trades today at $43.91.
BSX next reports on October 21. The last print saw a modest one-day decline of 0.1%, followed by a 3.6% gain over five days. Analysts cutting targets ahead of earnings is a familiar setup. Whether insider buying at $48–$51 proves prescient depends heavily on what management says about procedure volumes and market share.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
